{
  "pmcid": "6530966",
  "sha256": "001a3bffbad6f1961358c01036ad24f59c0cbf8e41eaaa4554b2473c8d369b6a",
  "timestamp_utc": "2025-11-09T22:50:58.514260+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.139633972992183,
    "reading_ease": 26.42966417910452,
    "word_count": 201
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Meloxicam IV for Postoperative Pain Management"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "multicenter, randomised, double-blind, placebo- and active-controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "486 women aged 18-65 with moderate-to-severe pain were enrolled"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive a single dose of meloxicam IV (5-60 mg), placebo, or morphine (0.15 mg/kg)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluated the efficacy and safety of meloxicam IV in reducing postoperative pain and opioid consumption"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The coprimary outcomes were summed pain intensity difference (SPID 24) and total pain relief (TOTPAR 24) over 24 hours"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was centralised with allocation concealment"
      },
      "Blinding": {
        "score": 3,
        "evidence": "blinding included patients, clinicians, and outcome assessors"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "486 women aged 18-65 with moderate-to-severe pain were enrolled"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "All 486 participants were analysed"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Meloxicam IV and morphine significantly improved SPID 24 and TOTPAR 24 compared to placebo (p < 0.001). Effect sizes for meloxicam IV ranged from 1.25 to 2.05 SDs"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were generally mild, with no treatment-related serious adverse events reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered at ClinicalTrials.gov (NCT01084161)"
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by Recro Pharma, Inc."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}